Records ?

Pediatric Pancreas Transplant Recipient Registration Worksheet

FORM APPROVED: O.M.B. NO. 0915-0157 Expiration Date: 12/31/2011 Note: These worksheets are provided to function as a guide to what data will be required in the online TIEDI® application. Currently in the worksheet, a red asterisk is displayed by fields that are required, independent of what other data may be provided. Based on data provided through the online TIEDI® application, additional fields that are dependent on responses provided in these required fields may become required as well. However, since those fields are not required in every case, they are not marked with a red asterisk.

Name:	DOB:
SSN:	Gender:
HIC:	Tx Date:
State of Permanent Residence: *	
Permanent Zip: 米	
[
Recipient Center:	
Surgeon Name: 🕊	
NPI#: *	
UNOS Donor ID #:	
Donor Type:	
Primary Diagnosis: 米	
Specify:	
Date: Last Seen, Retransplanted or Death st	
Patient Status: *	C DEAD
	C
Primary Cause of Death:	
Specify:	

Contributory Cause of Death: Specify:	
Contributory Cause of Death: Specify:	
Transplant Hospitalization: Date of Admission to Tx Center: * Date of Discharge from Tx Center: Was patient hospitalized during the last 90 days prior to the transplant admission:	
Medical Condition at time of transplant: *	 IN INTENSIVE CARE UNIT HOSPITALIZED NOT IN ICU NOT HOSPITALIZED
Functional Status: *	
Cognitive Development: *	 Definite Cognitive delay/impairment Probable Cognitive delay/impairment Questionable Cognitive delay/impairment No Cognitive delay/impairment Not Assessed
Motor Development: *	 Definite Motor delay/impairment Probable Motor delay/impairment Questionable Motor delay/impairment

	No Motor delay/imp	pairment
	O Not Assessed	
	C Within One Grade	Level of Peers
	C Delayed Grade Lev	vel
Academic Progress: *	C Special Education	
	Not Applicable < 5	years old/ High School graduate or GED
	C Status Unknown	
	0	
	Full academic load	
	Reduced academic	bload
Academic Activity Level: 米		te in academics due to disease or condition
		years old/ High School graduate or GED
	C Status Unknown	
Source of Payment:		
Primary: *		
Specify:		
Secondary:		
Date of Measurement:		
Height: *	ftin.	cm ST=
Weight: *	lbs	kg ST=
BMI:	kg/m ²	···g •···-
Previous Transplants:		
Previous Transplant Organ	Previous Transplant Date	Previous Transplant Graft Fail Date

The three most recent transplants are listed here. Please contact the UNet Help Desk to confirm more than three previous transplants by calling 800-978-4334 or by emailing unethelpdesk @unos.org.

Pretransplant Dialysis: *	0	YES NO UNK	
If Yes, Date of Most Recent Initiation of Chronic Maintenance Dialysis:			ST=
Average Daily Insulin Units: *			ST=
Serum Creatinine at Time of Tx: *		mg/dl	ST=
Viral Detection:			
	0	Positive	
HIV Serostatus: *	0	Negative	
	0	Not Done	
	0	UNK/Cannot Disclose	
	0	Positive	
	0	Negative	
CMV IgG: *	0	Not Done	
	0	UNK/Cannot Disclose	
	0	Positive	
	0	Negative	
CMV lgM: ★	0	Not Done	
	0	UNK/Cannot Disclose	
	0	Positive	
	0	Negative	
HBV Core Antibody: *	0	Not Done	
	0	UNK/Cannot Disclose	
	0	Positive	
HBV Surface Antigen: *	0	Negative	

	0	Not Done					
	0	UNK/Cannot Disclose					
	0	Positive					
HCV Serostatus: *	0	Negative					
nov Selosialus. •••	0	Not Done					
	0	UNK/Cannot Disclose					
	0	Positive					
EBV Serostatus: *	0	Negative					
	0	Not Done					
	0	UNK/Cannot Disclose					
Malignancies between listing and transplant: st	0	YES NO UNK					
This question is NOT applicable for patients receiving living de	onor tra	insplants who were never on the waiting list.					
		Skin Melanoma					
		Skin Non-Melanoma					
		CNS Tumor					
		CNS Tumor					
If yes, specify type:		CNS Tumor Genitourinary					
If yes, specify type:		CNS Tumor Genitourinary Breast					
If yes, specify type:		CNS Tumor Genitourinary Breast Thyroid					
If yes, specify type:		CNS Tumor Genitourinary Breast Thyroid Tongue/Throat/Larynx					
If yes, specify type:		CNS Tumor Genitourinary Breast Thyroid Tongue/Throat/Larynx					
If yes, specify type:		CNS Tumor Genitourinary Breast Thyroid Tongue/Throat/Larynx Lung Leukemia/Lymphoma					

Multiple Organ Recipient		
Were extra vessels used in the transplant procedure: Vessel Donor ID:		
Procedure Type:		
Surgical Information:		
If a simultaneous Tx with another organ, was the Pancreas revascularized before or after other organs:	0 0 0 0	Before Simultaneous After Not Applicable
Surgical Incision:	0 0 0	Left Midline Other Right
Graft Placement: *	0 0 0	INTRA-PERITONEAL RETRO-PERITONEAL PARTIAL INTRA/RETRO-PERITONEAL
Operative Technique: *	0 0 0	PANCREAS ALONE CLUSTER MULTI-ORGAN NON-CLUSTER

	0	PANCREAS AFTER KIDNEY						
	0	PANCREAS WITH KIDNEY DIFFERENT DONOR						
	0	ENTERIC W/ROUX-EN-Y						
	0	ENTERIC W/O ROUX-EN-Y						
	0	CYSTOSTOMY						
Duct Management: *	0	DUCT INJECTION IMMEDIATE						
	0	DUCT INJECTION DELAYED						
	0	OTHER SPECIFY						
Specify:								
	0	SYSTEMIC SYSTEM (ILIAC:CAVA)						
Venous Vascular Management: *	0	PORTAL SYSTEM (PORTAL OR TRIBUTARIES)						
	0	NA/Multi-organ cluster						
	0	CELIAC WITH PANCREAS						
	0	Y-GRAFT TO SPA & SMA						
N N N	0	SPA TO SMA DIRECT						
Arterial Reconstruction: *	0	SPA TO SMA WITH INTERPOSITION						
	0	SPA ALONE						
	0	OTHER SPECIFY						
Specify:								
Venous Extension Graft: *	0	YES NO						
Preservation Information:								
Total Pancreas Preservation Time (include Cold, Warm, Anastomotic time): *		hrs ST=						
1								

Pancreas Graft Status: *	0	Functioning Partial	Function Failed			
If death is indicated for the recipient, and the death was a result of some other factor unrelated to graft failure, select Functioning.						
		Insulin				
Method of blood sugar control: (check all that apply)		Oral medication				
		Diet				
		No Treatment				
Date insulin/medication first resumed:						
Date of Graft Failure:						
Pancreas Graft Removed:	0		NK			
Date Pancreas Graft Removed:						
Pancreas Primary Cause of Graft Failure:						
Specify:						
Contributory causes of graft failure:						
Pancreas Graft/Vascular Thrombosis:	0		NK			
Pancreas Infection:	0		NK			
Bleeding:	0		NK			
Anastomotic Leak:	0		NK			
Hyperacute Rejection:	0		NK			
Pancreas Acute Rejection:	0		NK			
Biopsy Proven Isletitis:	0		NK			
Pancreatitis:	0		NK			
Other, Specify:						

Pancreas Transplant Complications:

(Not leading to graft failure.)

Pancreatitis: *	
Anastomotic Leak: *	
Abcess or Local Infection: *	
Pancreas Transplant Complications: Other	
	0
Did patient have any acute rejection episodes between transplant and discharge: *	 Yes, at least one episode treated with anti-rejection agent Yes, none treated with additional anti-rejection agent No
Was biopsy done to confirm acute rejection:	 Biopsy not done Yes, rejection confirmed
	Yes, rejection not confirmed
Biological or Anti-viral Therapy:	C YES NO Unknown/Cannot disclose
If Yes, check all that apply:	Acyclovir (Zovirax) Cytogam (CMV) Gamimune Gammagard Ganciclovir (Cytovene)
	 Valgancyclovir (Valcyte) HBIG (Hepatitis B Immune Globulin) Flu Vaccine (Influenza Virus) Lamivudine (Epivir) (for treatment of Hepatitis B)

		Other, Specify
		Valacyclovir (Valtrex)
Specify:		
Specify:		
Other therapies:	0	YES NO
		Photopheresis
If Yes, check all that apply:		Plasmapheresis
		Total Lymphoid Irradiation (TLI)
Are any medications given currently for maintenance or anti-rejection: $lpha$	0	YES NO
Did the patient participate in any clinical research protocol for immunosuppressive medications:	0	YES NO
If Yes, Specify:		
View Immunosuppressive Medications		

Definitions Of Immunosuppressive Medications

For each of the immunosuppressant medications listed, check **Previous Maintenance (Prev Maint)**, **Current Maintenance (Curr Maint)** or **Anti**rejection (AR) to indicate all medications that were prescribed for the recipient during this follow-up period, and for what reason. If a medication was not given, leave the associated box(es) blank.

Previous Maintenance (Prev Maint) includes all immunosuppressive medications given during the report period, which covers the period from the last clinic visit to the current clinic visit, for varying periods of time which may be either long-term or intermediate term with a tapering of the dosage until the drug is either eliminated or replaced by another long-term maintenance drug (example: Prednisone, Cyclosporine, Tacrolimus, Mycophenolate Mofetil, Azathioprine, or Rapamycin). This does not include any immunosuppressive medications given to treat rejection episodes.

Current Maintenance (Curr Maint) includes all immunosuppressive medications given at the current clinic visit to begin in the next report for varying periods of time which may be either long-term or intermediate term with a tapering of the dosage until the drug is either eliminated or replaced by another long-term maintenance drug (example: Prednisone, Cyclosporine, Tacrolimus, Mycophenolate Mofetil, Azathioprine, or Rapamycin). This does not include any immunosuppressive medications given to treat rejection episodes.

Anti-rejection (AR) immunosuppression includes all immunosuppressive medications given for the purpose of treating an acute rejection episode since the last clinic visit (example: Methylprednisolone, Atgam, OKT3, or Thymoglobulin). When switching maintenance drugs (example: from Tacrolimus to Cyclosporine; or from Mycophenolate Mofetil to Azathioprine) because of rejection, the drugs <u>should not</u> be listed under AR immunosuppression. Note: The Anti-rejection field refers to any anti-rejection medications since the last clinic visit, not just at the time of the current clinic visit.

If an immunosuppressive medication other than those listed is being administered (e.g., new monoclonal antibodies), select Previous Maint, or Current Maint, or AR next to Other Immunosuppressive Medication field, and enter the full name of the medication in the space provided. <u>Do not list non-immunosuppressive medications</u>. For each of the immunosuppressive medications listed, select **Ind** (Induction), **Maint** (Maintenance) or **AR** (Anti-rejection) to indicate all medications that were prescribed for the recipient during the initial transplant hospitalization period, and for what reason. If a medication was not given, leave the associated box(es) blank.

Induction (Ind) immunosuppression includes all medications given for a short finite period in the perioperative period for the purpose of preventing acute rejection. Though the drugs may be continued after discharge for the first 30 days after transplant, it <u>will not</u> be used long-term for immunosuppressive maintenance. Induction agents are usually polyclonal, monoclonal, or IL-2 receptor antibodies (example: Methylprednisolone, Atgam, Thymoglobulin, OKT3, Simulect, or Zenapax). Some of these drugs might be used for another finite period for rejection therapy and would be recorded as rejection therapy if used for this reason. For each induction medication indicated, write the <u>total number of days the drug was actually</u> administered in the space provided. For example, if Simulect or Zenapax was given in 2 doses a week apart, then the total number of days would be 2, even if the second dose was given after the patient was discharged.

Maintenance (Maint) includes all immunosuppressive medications given before, during or after transplant for varying periods of time which may be either long-term or intermediate term with a tapering of the dosage until the drug is either eliminated or replaced by another long-term maintenance drug (example: Prednisone, Cyclosporine, Tacrolimus, Mycophenolate Mofetil, Azathioprine, or Rapamycin). This does not include any immunosuppressive medications given to treat rejection episodes, or for induction.

Anti-rejection (AR) immunosuppression includes all immunosuppressive medications given for the purpose of treating an acute rejection episode during the initial post-transplant period or during a specific follow-up period, usually up to 30 days after the diagnosis of acute rejection (example: Methylprednisolone, Atgarn, OKT3, or Thymoglobulin). When switching maintenance drugs (example: from Tacrolimus to Cyclosporine; or from Mycophenolate Mofetil to Azathioprine) because of rejection, the drugs <u>should not</u> be listed under AR immunosuppression, but <u>should be</u> listed under maintenance immunosuppression.

If an immunosuppressive medication other than those listed is being administered (e.g., new monoclonal antibodies), select Ind, Maint, or AR next to Other Immunosuppressive Medication field, and enter the full name of the medication in the space provided. <u>Do not list non-immunosuppressive</u> <u>medications.</u>

	In	d.	Days	ST	Maint	AR
Steroids (Prednisone,Methylprednisolone,Solumedrol,Medrol,Deca dron)	r					
Atgam (ATG)	r					
OKT3 (Orthoclone, Muromonab)	ſ					
Thymoglobulin	r					
Simulect - Basiliximab	ſ					
Zenapax - Daclizumab	r					
Azathioprine (AZA, Imuran)	r					
EON (Generic Cyclosporine)	r					
Gengraf (Abbott Cyclosporine)	r					
Other generic Cyclosporine, specify brand:	ſ					
Neoral (CyA-NOF)	ſ					
Sandimmune (Cyclosporine A)	r					
CellCept (Mycophenolate Mofetil; MMF)	ſ					

Generic MMF (Generic CellCept)			
Prograf (Tacrolimus, FK506)			
Generic Tacrolimus (Generic Prograf)			
Advagraf (Tacrolimus Extended or Modified Release)			
Nulojix (Belatacept)			
Sirolimus (RAPA, Rapamycin, Rapamune)			
Myfortic (Mycophenolate Sodium)			

	Ind.	Days	ST	Maint	AR
Campath - Alemtuzumab (anti-CD52)					
Cyclophosphamide (Cytoxan)					
Leflunomide (LFL, Arava)					
Methotrexate (Folex, PFS, Mexate-AQ, Rheumatrex)					
Other Immunosuppressive Medication, Specify					
Rituximab					
	Ind.	Days	ST	Maint	AR
Zortress (Everolimus)					
Other Immunosuppressive Medication, Specify					